U.S. markets closed

CytomX Therapeutics, Inc. (CTMX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
5.26-0.18 (-3.31%)
At close: 4:00PM EDT
5.15 -0.11 (-2.09%)
After hours: 04:53PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close5.44
Open5.39
Bid5.28 x 1100
Ask5.29 x 3000
Day's Range5.23 - 5.45
52 Week Range4.28 - 10.05
Volume373,072
Avg. Volume703,912
Market Cap342.726M
Beta (5Y Monthly)0.69
PE Ratio (TTM)N/A
EPS (TTM)-1.17
Earnings DateNov 03, 2021 - Nov 08, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est13.14
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • CytomX Therapeutics, Inc.
    NKTR: Raising target price to $14.00NEKTAR THERAPEUTICS has an Investment Rating of SELL; a target price of $14.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Medium.
    Rating
    Fair Value
    Economic Moat
    3 days agoArgus Research
View more
  • GlobeNewswire

    CytomX Therapeutics Announces New Employment Inducement Grants

    SOUTH SAN FRANCISCO, Calif., Sept. 16, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage, oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated therapeutics based on its Probody® technology platform, today announced that on September 15, 2021, the Company granted nine new employees options to purchase a total of 157,200 shares of the Company’s common stock at an exercise price per share equal to $4.97, whi

  • GlobeNewswire

    CytomX Therapeutics to Present at H.C. Wainwright 23rd Annual Global Investment Conference

    SOUTH SAN FRANCISCO, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated therapeutics based on its Probody® technology platform, today announced that Sean McCarthy, D.Phil., president, chief executive officer, and chairman, will participate in a virtual fireside chat at the H.C. Wainwright 23rd Annual Global Investment Conference, being

  • Simply Wall St.

    Is CytomX Therapeutics (NASDAQ:CTMX) In A Good Position To Deliver On Growth Plans?

    We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...